VTRS: Viatris Inc. Growth-Adjusted Payback Ratio

Viatris Inc. (VTRS) reliability in supplying critical medications is constrained by low margins in the generics sector and pressure from Asian manufacturers. The adjusted P/E to growth ratio visualizes these risks, where 0.92 serves as the current parameter value. To stabilize, Viatris Inc. (VTRS) is expanding into emerging markets and complex therapeutic niches, which helps overcome stagnation in mature regions.

VTRS Viatris Inc Price/Earnings to Growth Ratio (07/04/2022 - 11/14/2026)

Analytical breakdowns for Viatris Inc. (VTRS)

- share price and consensus valuation forecast:

Price Performance Chart Viatris Inc|VTRS - Analyst Consensus Forecast

- market capitalization information:

Market Value Viatris Corp|VTRS - Total Company Value

- book capitalization indicators:

Net Asset Value per Share Viatris|VTRS - Company Book Value|Market Value to Book Value Ratio viatris.com|VTRS - Company Total Assets

- issuer credit burden and liquidity indicators:

- earnings and multiples data:

VTRS - Net Profit|Company Profit Forecast Viatris Inc.|VTRS - P/E Multiple|Forward P/E Multiple Mylan|VTRS - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Viatris Corp|VTRS - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Viatris|VTRS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months viatris.com|VTRS - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Viatris Inc.

- total revenue and sales volume data:

VTRS - Company Sales|Company Future Revenue Viatris Inc|VTRS - P/S Multiple|Market Cap to Expected Sales Ratio Viatris Corp

Fundamental company analysis:Viatris Inc (VTRS)

To objectively value Viatris Inc. (VTRS), it is necessary to correlate the share price with earnings growth, which allows for the determination of a fair value based on the PEG ratio. This indicator reveals an undervalued asset when the value is below one, reflecting the effectiveness of Scott Smith's portfolio transformation and the pace of debt repayment through the sale of non-core assets to develop high-margin drugs.

Competing companies

LLY (Lilly) - Growth-Adjusted Payback Ratio|PEG Multiple ABBV (Abbvie)|Growth-Adjusted Payback Ratio AZN|NVS - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate merck.com|Novo Nordisk (NVO) - Price/Earnings to Growth Ratio|AMGN (Amgen Corp) - Price/Earnings to Growth Ratio|PFE (Pfizer Corporation) - PEG Multiple|Growth-Adjusted P/E Ratio SNY (Sanofi Group)|PEG Multiple BMY|Growth-Adjusted Market Cap to Net Income gsk.com|Price/Earnings to Growth Ratio Takeda TAK|TEVA: Growth-Adjusted P/E Ratio|Dr. Reddy's Lab - PEG Multiple|Price to Net Income Growth Ratio Roivant Corp (ROIV)|ZLAB (Zai Lab Limited) - Price/Earnings to Growth Multiple|BHC (bauschhealth.com) - Price/Earnings to Growth Ratio|COSM (Cosmos Health) - PEG Multiple